SEARCH

SEARCH BY CITATION

References

  • 1
    Stafforini DM, Elstad MR, McIntyre TM, Zimmerman GA, Prescott SM. Human macrophages secret platelet-activating factor acetylhydrolase. J Biol Chem 1990; 265: 96827.
  • 2
    Kolodgie FD, Burke AP, Skorija KS et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 25239.
  • 3
    Rosenson RS. Lp-PLA2 and risk of atherosclerotic vascular disease. Lancet 2010; 375: 1498500.
  • 4
    Stafforini DM, Tjoelker LW, McCormick SP et al. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem 1999; 274: 701824.
  • 5
    Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005; 25: 92331.
  • 6
    Karabina SA, Elisaf M, Bairaktari E, Tzallas C, Siamopoulos KC, Tselepis AD. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Invest 1997; 27: 595602.
  • 7
    MacPhee CH, Moores KE, Boyd HF et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999; 338 (Pt 2): 47987.
  • 8
    Tjoelker LW, Wilder C, Eberhardt C et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995; 374: 54953.
  • 9
    US Food and Drug Administration. URL http://www.accessdata.fda.gov/cdrh_docs/pdf5/K050523.pdf [accessed on 16 June 2010).
  • 10
    The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial (STABILITY) URL http://clinicaltrials.gov/ct2/show/NCT00799903 [accessed on 16 June 2010].
  • 11
    Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007; 82: 15965.
  • 12
    Van Vark LC, Kardys I, Bleumink GS et al. Lipoprotein-associated phospholipase A2 activity and risk of heart failure: the Rotterdam study. Eur Heart J 2006; 27: 234652.
  • 13
    Gerber Y, Dunlay SM, Jaffe AS et al. Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community. Atherosclerosis 2009; 203: 5938.
  • 14
    Suzuki T, Solomon C, Jenny NS et al. Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study. Circ Heart Fail 2009; 2: 42936.
  • 15
    MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 722.
  • 16
    MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999; 20: 72541.
  • 17
    MRC/BHF Heart Protection Study Collaborative Group. N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol 2007; 49: 3119.
  • 18
    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 46170.
  • 19
    Plummer M. Improved estimates of floating absolute risk. Stat Med 2004; 23: 93104.
  • 20
    Lp-PLA2 Studies Collaboration. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375: 153644.
  • 21
    Clarke R, Emberson JR, Parish S et al. Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men. Arch Intern Med 2007; 167: 13738.
  • 22
    Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 19932000.
  • 23
    Clarke R, Shipley M, Lewington S et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999; 150: 34153.
  • 24
    Shimokata K, Yamada Y, Kondo T et al. Association of gene polymorphisms with coronary artery disease in individuals with or without nonfamilial hypercholesterolemia. Atherosclerosis 2004; 172: 16773.
  • 25
    Yamada Y, Matsuo H, Segawa T et al. Assessment of genetic risk for myocardial infarction. Thromb Haemost 2006; 96: 2207.
  • 26
    Hou L, Chen S, Yu H et al. Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study. Hum Genet 2009; 125: 1120.
  • 27
    Jang Y, Kim OY, Koh SJ et al. The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men. J Clin Endocrinol Metab 2006; 91: 35217.
  • 28
    Mohler ER 3rd, Ballantyne CM, Davidson MH et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2008; 51: 163241.
  • 29
    Serruys PW, Garcia-Garcia HM, Buszman P et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008; 118: 117282.
  • 30
    Wilensky RL, Shi Y, Mohler ER 3rd et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008; 14: 105966.
  • 31
    The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial (SOLID-TIMI 52). URL http://clinicaltrials.gov/ct2/show/NCT01000727 [accessed on 16 June 2010].